COSCIENS Biopharma Inc. (TSX: CSCI.TO) Stock Competitors & Peer Comparison

COSCIENS Biopharma Inc. (TSX: CSCI.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSCI.TO stands at 2.7M. In comparison, LLY.TO has a market cap of 1.5T. Regarding current trading prices, CSCI.TO is priced at CA$7.70 on the TSX, while LLY.TO trades at CA$42.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSCI.TO currently has a P/E ratio of -0.25, whereas LLY.TO's P/E ratio is 39.27. In terms of profitability, CSCI.TO's ROE is -0.93%, compared to LLY.TO's ROE of N/A. Regarding short-term risk, CSCI.TO is more volatile compared to LLY.TO. This indicates higher risk in terms of short-term price fluctuations for CSCI.TO.Check LLY.TO's competition here

COSCIENS Biopharma Inc. (TSX: CSCI.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSCI.TO stands at 2.7M. In comparison, NBLY.TO has a market cap of 835.5M. Regarding current trading prices, CSCI.TO is priced at CA$7.70 on the TSX, while NBLY.TO trades at CA$18.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSCI.TO currently has a P/E ratio of -0.25, whereas NBLY.TO's P/E ratio is -25.48. In terms of profitability, CSCI.TO's ROE is -0.93%, compared to NBLY.TO's ROE of -0.03%. Regarding short-term risk, CSCI.TO is more volatile compared to NBLY.TO. This indicates higher risk in terms of short-term price fluctuations for CSCI.TO.Check NBLY.TO's competition here

COSCIENS Biopharma Inc. (TSX: CSCI.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSCI.TO stands at 2.7M. In comparison, CYBN.NE has a market cap of 256.6M. Regarding current trading prices, CSCI.TO is priced at CA$7.70 on the TSX, while CYBN.NE trades at CA$10.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSCI.TO currently has a P/E ratio of -0.25, whereas CYBN.NE's P/E ratio is -2.05. In terms of profitability, CSCI.TO's ROE is -0.93%, compared to CYBN.NE's ROE of -0.72%. Regarding short-term risk, CSCI.TO is less volatile compared to CYBN.NE. This indicates lower risk in terms of short-term price fluctuations for CSCI.TO.Check CYBN.NE's competition here

COSCIENS Biopharma Inc. (TSX: CSCI.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSCI.TO stands at 2.7M. In comparison, MDP.TO has a market cap of 159.6M. Regarding current trading prices, CSCI.TO is priced at CA$7.70 on the TSX, while MDP.TO trades at CA$5.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSCI.TO currently has a P/E ratio of -0.25, whereas MDP.TO's P/E ratio is -53.31. In terms of profitability, CSCI.TO's ROE is -0.93%, compared to MDP.TO's ROE of -0.05%. Regarding short-term risk, CSCI.TO is less volatile compared to MDP.TO. This indicates lower risk in terms of short-term price fluctuations for CSCI.TO.Check MDP.TO's competition here

COSCIENS Biopharma Inc. (TSX: CSCI.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSCI.TO stands at 2.7M. In comparison, NOVC.TO has a market cap of 108M. Regarding current trading prices, CSCI.TO is priced at CA$7.70 on the TSX, while NOVC.TO trades at CA$1.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSCI.TO currently has a P/E ratio of -0.25, whereas NOVC.TO's P/E ratio is 34.80. In terms of profitability, CSCI.TO's ROE is -0.93%, compared to NOVC.TO's ROE of +0.06%. Regarding short-term risk, CSCI.TO is more volatile compared to NOVC.TO. This indicates higher risk in terms of short-term price fluctuations for CSCI.TO.Check NOVC.TO's competition here

COSCIENS Biopharma Inc. (TSX: CSCI.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSCI.TO stands at 2.7M. In comparison, CBST.NE has a market cap of 17.5M. Regarding current trading prices, CSCI.TO is priced at CA$7.70 on the TSX, while CBST.NE trades at CA$0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSCI.TO currently has a P/E ratio of -0.25, whereas CBST.NE's P/E ratio is -0.05. In terms of profitability, CSCI.TO's ROE is -0.93%, compared to CBST.NE's ROE of +1.07%. Regarding short-term risk, CSCI.TO is more volatile compared to CBST.NE. This indicates higher risk in terms of short-term price fluctuations for CSCI.TO.Check CBST.NE's competition here

COSCIENS Biopharma Inc. (TSX: CSCI.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSCI.TO stands at 2.7M. In comparison, FAF.TO has a market cap of 13.1M. Regarding current trading prices, CSCI.TO is priced at CA$7.70 on the TSX, while FAF.TO trades at CA$0.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSCI.TO currently has a P/E ratio of -0.25, whereas FAF.TO's P/E ratio is -0.14. In terms of profitability, CSCI.TO's ROE is -0.93%, compared to FAF.TO's ROE of -0.97%. Regarding short-term risk, CSCI.TO is less volatile compared to FAF.TO. This indicates lower risk in terms of short-term price fluctuations for CSCI.TO.Check FAF.TO's competition here

COSCIENS Biopharma Inc. (TSX: CSCI.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSCI.TO stands at 2.7M. In comparison, GABY.CN has a market cap of 3.7M. Regarding current trading prices, CSCI.TO is priced at CA$7.70 on the TSX, while GABY.CN trades at CA$0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSCI.TO currently has a P/E ratio of -0.25, whereas GABY.CN's P/E ratio is -0.08. In terms of profitability, CSCI.TO's ROE is -0.93%, compared to GABY.CN's ROE of +3.03%. Regarding short-term risk, CSCI.TO is more volatile compared to GABY.CN. This indicates higher risk in terms of short-term price fluctuations for CSCI.TO.Check GABY.CN's competition here

COSCIENS Biopharma Inc. (TSX: CSCI.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSCI.TO stands at 2.7M. In comparison, IWIN.CN has a market cap of 1M. Regarding current trading prices, CSCI.TO is priced at CA$7.70 on the TSX, while IWIN.CN trades at CA$0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSCI.TO currently has a P/E ratio of -0.25, whereas IWIN.CN's P/E ratio is -0.05. In terms of profitability, CSCI.TO's ROE is -0.93%, compared to IWIN.CN's ROE of -0.21%. Regarding short-term risk, CSCI.TO is more volatile compared to IWIN.CN. This indicates higher risk in terms of short-term price fluctuations for CSCI.TO.Check IWIN.CN's competition here

COSCIENS Biopharma Inc. (TSX: CSCI.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSCI.TO stands at 2.7M. In comparison, TREE.NE has a market cap of 1M. Regarding current trading prices, CSCI.TO is priced at CA$7.70 on the TSX, while TREE.NE trades at CA$0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSCI.TO currently has a P/E ratio of -0.25, whereas TREE.NE's P/E ratio is -0.17. In terms of profitability, CSCI.TO's ROE is -0.93%, compared to TREE.NE's ROE of -4.86%. Regarding short-term risk, CSCI.TO is more volatile compared to TREE.NE. This indicates higher risk in terms of short-term price fluctuations for CSCI.TO.Check TREE.NE's competition here

COSCIENS Biopharma Inc. (TSX: CSCI.TO) plays a significant role within the Healthcare sector. Its performance on the TSX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSCI.TO stands at 2.7M. In comparison, MOOD.CN has a market cap of 877.6K. Regarding current trading prices, CSCI.TO is priced at CA$7.70 on the TSX, while MOOD.CN trades at CA$0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSCI.TO currently has a P/E ratio of -0.25, whereas MOOD.CN's P/E ratio is -6.03. In terms of profitability, CSCI.TO's ROE is -0.93%, compared to MOOD.CN's ROE of -0.85%. Regarding short-term risk, CSCI.TO is less volatile compared to MOOD.CN. This indicates lower risk in terms of short-term price fluctuations for CSCI.TO.Check MOOD.CN's competition here